Cholesterol gene-editing trial reports reductions at one year


The 15-patient study reported sustained reductions in blood fats after one CTX310 infusion. The treatment remains experimental, and the findings do not establish fewer heart attacks or long-term safety.
A Cleveland Clinic trial reported that reductions in cholesterol and triglycerides persisted one year after a single infusion of experimental gene-editing treatment CTX310. Among participants receiving the highest dose, LDL cholesterol—often called “bad” cholesterol—was 52.5% below its pretreatment level, while triglycerides, another type of blood fat, were 47.8% lower, according to ScienceDaily.
The first-in-human Phase 1 trial, an early stage of clinical testing, followed 15 patients whose blood-fat disorders had not responded adequately to medications. Researchers wanted to find out whether reductions previously reported after two months would continue. The year-long results extend the evidence that the effect can last, but the reported percentages apply to the highest-dose participants, not to the entire trial.
CTX310 carries CRISPR-Cas9, a system for making targeted changes to DNA, to the liver. There, it switches off ANGPTL3, a gene that helps regulate fats circulating in the blood. Disabling this gene can lower both LDL cholesterol and triglycerides, which are associated with cardiovascular disease.
That makes the blood-fat reductions relevant to cardiovascular research. But a 52.5% fall in LDL cholesterol is not a 52.5% reduction in heart attacks: the reported figures measure changes in blood-fat levels, not whether patients experienced fewer heart attacks.
No serious adverse events related to CTX310 were reported during the one-year follow-up. That is an early safety observation from just 15 people, not proof of long-term safety. CTX310 remains experimental.
ScienceDaily reports that the findings were presented at the 2026 European Society of Cardiology annual meeting and published simultaneously in the New England Journal of Medicine. CRISPR Therapeutics AG funded the study, and the institution of first author Luke Laffin, a Cleveland Clinic cardiologist, has received research funding from the company.
Researchers plan another 15 years of safety follow-up after the initial year, in line with US Food and Drug Administration recommendations for gene-editing therapies. That monitoring will address safety over a much longer period than the results reported so far.

Laboratory results prompted the additional experiment. A four-Martian-day plan left room for its energy demands alongside observations and checks of material left by drilling.
3 min

More than 12,000 fossils and rock chemistry support an early need for oxygen, but do not establish that oxygen caused complex cells to originate.

Minerals from the eruption closely matched their historically known age, helping researchers improve a method used to date volcanic events and compare Earth’s past events.
3 min